Archived Bulletins

June 20, 2018

Published: June 20, 2018
Category: News
CCTG staff is raising funds and awareness for the fight against cancer

The CCTG TRIALBLAZERS have been training hard for this year’s Kingston Relay for Life, June 22, 2018 - 6:00 pm - 12:00 am.

Read More

PA.6 Clinical trial: Dr. Jim Biagi and trial participant Kathleen Kennedy

The PRODIGE 24/CCTG PA.6 trial results suggest that this pancreatic cancer treatment regimen should become standard practice world-wide. Patients who receive this treatment after surgery are almost twice as likely to survive.

Read More

Published: June 20, 2018
Category: Publications

New results from the groundbreaking “Trial Assigning Individualized Options for Treatment Rx” (TAILORx) breast cancer trial (CCTG MAC.12 in Canada), show no benefit from chemotherapy for 70% of women with the most common form of breast cancer. The study found that for a group of women with hormone receptor (HR)-positive, HER2 negative, axillary lymph node-negative breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more beneficial than with hormone therapy alone.

Read More

June 06, 2018

Published: June 06, 2018
Category: Trials

PNC.1 (EA8134), InPACT: International Penile Advanced Cancer Trial, has been centrally activated in Canada.

Read More

Published: June 06, 2018
Category: Trials

CCTG MA.39 TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER has been centrally activated in Canada

Read More

Published: June 06, 2018
Category: Group updates

A great opportunity to join our team: The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a Monitor/Auditor.

Position Title: Monitor/Auditor
Competition Number: J0518-0333

Read More

Clinical trials are not always about finding a new drugs that works, sometimes they look at what treatments, or what doses, are necessary for patients.

Read More

Study results suggest that a new pancreatic cancer treatment become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery. The randomized phase III clinical trial was sponsored by the academic cancer research groups of UNICANCER, in Paris, France and the Canadian Cancer Trials Group (CCTG). The results show that the risk of cancer recurring in post-operative pancreatic cancer patients was reduced by almost 50% with the mFOLFIRINOX chemotherapy combination.

Read More